In cross-sectional studies, chronic helminth infections have been associated with immunological hyporesponsiveness that can affect responses to unrelated antigens. To study the immunological effects of deworming, we conducted a cluster-randomized, double-blind, placebo-controlled trial in Indonesia and assigned 954 households to receive albendazole or placebo once every 3 mo for 2 y. Helminthspecific and nonspecific whole-blood cytokine responses were assessed in 1,059 subjects of all ages, whereas phenotyping of regulatory molecules was undertaken in 121 school-aged children. All measurements were performed before and at 9 and 21 mo after initiation of treatment. Anthelmintic treatment resulted in significant increases in proinflammatory cytokine responses to helminths | albendazole | cytokine responses | Indonesia | deworming S oil-transmitted helminths (STHs) represent the most common infectious disease worldwide (1). In addition to specific worm-associated morbidities, it has been argued that chronic STH infections may magnify health-related burdens in communities remote from health care facilities, exacerbating anemia, poor nutritional status, and possibly poor cognitive development (1). However, this was not fully supported by the latest analysis of the Cochrane database (2).
In cross-sectional studies, chronic helminth infections have been associated with immunological hyporesponsiveness that can affect responses to unrelated antigens. To study the immunological effects of deworming, we conducted a cluster-randomized, double-blind, placebo-controlled trial in Indonesia and assigned 954 households to receive albendazole or placebo once every 3 mo for 2 y. Helminthspecific and nonspecific whole-blood cytokine responses were assessed in 1,059 subjects of all ages, whereas phenotyping of regulatory molecules was undertaken in 121 school-aged children. All measurements were performed before and at 9 and 21 mo after initiation of treatment. Anthelmintic treatment resulted in significant increases in proinflammatory cytokine responses to Plasmodium falciparum-infected red blood cells (PfRBCs) and mitogen, with the largest effect on TNF responses to PfRBCs at 9 moestimate [95% confidence interval], 0.37 [0. .53], P value over time (P time ) < 0.0001. Although the frequency of regulatory T cells did not change after treatment, there was a significant decline in the expression of the inhibitory molecule cytotoxic T lymphocyteassociated antigen 4 (CTLA-4) on CD4
+ T cells of albendazoletreated individuals, -0.060 [-0.107 to -0.013] and -0.057 [-0.105 to -0.008] at 9 and 21 mo, respectively; P time = 0.017. This trial shows the capacity of helminths to up-regulate inhibitory molecules and to suppress proinflammatory immune responses in humans. This could help to explain the inferior immunological responses to vaccines and lower prevalence of inflammatory diseases in low-compared with high-income countries.
helminths | albendazole | cytokine responses | Indonesia | deworming S oil-transmitted helminths (STHs) represent the most common infectious disease worldwide (1) . In addition to specific worm-associated morbidities, it has been argued that chronic STH infections may magnify health-related burdens in communities remote from health care facilities, exacerbating anemia, poor nutritional status, and possibly poor cognitive development (1) . However, this was not fully supported by the latest analysis of the Cochrane database (2) .
Immunologically, cellular immune hyporesponsiveness is a hallmark of chronic helminth infections that may allow parasites' longterm survival (3) . The consequences of immunosuppression are manifold with potentially major public health relevance. Immune hyporesponsiveness could curtail effective immune responses, thereby increasing susceptibility to pathogens, and helminths are associated with suboptimal vaccine responses (4-6). The helminthrelated dampened immune responses might nevertheless help to prevent immunopathology during coinfections and, possibly, aberrant reactivity to environmental or self-antigens (7) . With respect to the latter, there is currently much interest in the use of helminth infections to treat allergies and autoimmune diseases, exploiting their ability to induce immune hyporesponsiveness (8) .
Suppressed lymphocyte responses were described in the 1970s (9) , but the evidence base has not moved much beyond animal models and cross-sectional studies in humans (10) . The cellular mechanisms associated with helminth-related immune hyporesponsiveness are not fully understood. Several regulatory cells and molecules are thought to play an important role in the regulatory network (3) . Within T-cell responses, expansion of Tregulatory cells (Tregs) is reported in both animal models (10) and some human studies (11, 12) . Tregs suppress helminthspecific and bystander proliferative and proinflammatory responses. Expression of T-cell-associated molecules, including cytotoxic T lymphocyte-associated antigen 4 (CTLA) and programmed death-1 (PD-1), may also be involved in helminthinduced hyporesponsiveness and spillover suppression (13) .
Significance
Chronic helminth infections are accompanied by profound immune regulation. In humans, helminth-induced immune reactivity has not been thoroughly investigated in trial settings. We assessed the effect of anthelmintic treatment on immune responses in a whole community in a placebo-controlled randomized controlled trial. We show increased immune responses to helminth-specific as well as unrelated antigens, in parallel with decreased expression of cytotoxic T lymphocyteassociated antigen 4 (CTLA-4), which is a molecule involved in putting the brake on immune activation. Deworming seems to lead to decreased immunoregulation and increased immune responsiveness. These findings are of importance regarding the suboptimal vaccine responses in helminth-endemic areas and also in anticipating the future rise in inflammatory diseases when helminth infections are increasingly controlled.
Longitudinal studies assessing the effect of anthelmintic treatment on cellular immune responsiveness are rare and either lack placebo controls, target children only, or measure immune responses at one time point posttreatment (14) (15) (16) . Moreover, none have examined the changes in regulatory cells or molecules. No large-scale community-based intervention studies to establish whether helminth infections lead to immune hyporesponsiveness in humans have been reported.
To disentangle the impact of helminths on the immune system from other influences, we conducted a household clusterrandomized, double-blind, placebo-controlled trial of albendazole once every 3 mo in communities with high STH prevalence on Flores island, Indonesia. Here we present results concerning the effects of anthelmintic treatment on cellular immune responses.
Results

Albendazole Treatment Reduces but Does Not Eliminate Helminth
Infections. Characteristics of the study participants (n = 1,059) are shown in Table 1 . At baseline, one or more helminth species were found in 88.7% of individuals, with hookworm being the most prevalent (77.1% of total). The trial consort diagram with follow-up data can be found in Fig. S1 . Albendazole treatment reduced the prevalence of geohelminths after 9 (51.9% vs. 84.1% for placebo) and 21 mo (39.2% vs. 80% for placebo) (Table S1 ). In the whole immunological study within Scientific Programme Indonesia-Netherlands (IMMUNOSPIN) trial, the prevalence of geohelminth infection was 87.3%, and albendazole treatment reduced prevalence of geohelminths after 9 (51.4% vs. 82.8% for placebo) and 21 mo (41.9% vs. 78.8% for placebo). As for the whole IMMUNOSPIN trial, the greatest effect was on hookworm followed by Ascaris, whereas the effect on Trichuris infections was less pronounced. Albendazole also reduced intensities of hookworm and Ascaris infections, as assessed by PCR (Fig. S2 ).
Helminth-Specific and Nonspecific Whole-Blood Cytokine Responses
Are Increased After Albendazole Treatment. Fig. 1 A and B shows the effect of treatment on cytokine responses at 9 mo and 21 mo, respectively. Regarding helminth-specific cytokines, Ascaris antigen (AscAg)-induced interleukin-2 (IL-2) production was significantly enhanced by treatment over the study period (P time = 0.018), with a significant increase in the treated group at 9 mo-estimate [95% confidence interval (CI)], 0.17 [0.05-0.28] (Fig. 1A) .
In response to plasmodial antigens (Plasmodium falciparuminfected red blood cells, PfRBCs), there was an increase over time in proinflammatory cytokine tumor necrosis factor (TNF; P time < 0.0001) and IFN-gamma (IFN-γ; P time = 0.036) after albendazole treatment. As shown in Fig. 1A , both TNF and IFN-γ were significantly higher in the albendazole compared with the placebo group at the 9-mo time point (0.37 [0.21-0.53] for TNF and 0.14 [0.03-0.24] for IFN-γ). To get an indication of the absolute changes in cytokine levels, TNF production to PfRBCs in the two groups at the 9-mo time point is shown in Fig. 1C . The differences in other statistically significant cytokine changes are shown in Fig. S3 . None of the significant changes in antigenspecific responses were correlated with worm burden before treatment (Table S2) .
Regarding the general adaptive response (cytokine responses to phytohemagglutinin, PHA), albendazole treatment significantly increased TNF and IL-10 secretion (P time = 0.011 and P time = 0.003, respectively) over the trial period; for TNF, albendazole treatment resulted in elevated responses at 9 mo, whereas for IL-10 the response was significantly higher after 21 mo (for TNF at 9 mo, 0. Albendazole did not affect responses to lipopolysaccharide (LPS) ( Table S3) . Cytokines in unstimulated blood revealed no treatment-related differences (Table S3) . IFN-γ responses to uninfected red blood cells (uRBCs) were not significantly different between treatment arms (P time = 0.91), however TNF production was increased posttreatment (P time = 0.018). This was only significant at 9 mo (9-mo estimate, 0.13 [0.01-0.25]; at 21 mo, -0.13 [-0.26-0.003]), although to a much lesser extent than the response to PfRBCs.
The Enhancement of Cytokine Responses Is Not a Direct Albendazole
Effect. To rule out albendazole as a direct cause of enhanced immune responses, we stratified the analysis on STH infection status at baseline (Table 2) . Enhanced PfRBC-induced TNF and IQR, interquartile range. *The number of positives (n) of the total population examined (N). † Diagnosed by PCR. ‡ Diagnosed by microscopy.
AscAg-induced IL-2 by albendazole treatment were seen in helminth-infected (P time = 0.0004 and P time = 0.006, respectively; Table 2 ) but not in uninfected subjects (Table 2 ) at 9 mo posttreatment. The effect of anthelmintic treatment on PHAstimulated TNF in the stratified analysis was seen at 9 mo posttreatment in the helminth-infected individuals, but over the trial period, this was not statistically significant (P time = 0.098; Table 2 , helminth-infected individuals). Corresponding background (unstimulated and uRBC-induced) cytokine responses were not increased in either helminth-infected or -uninfected subjects (Table S4) .
Changes in Cell Counts After Albendazole Treatment Do Not Explain
Changes in Cytokine Responses. To determine whether increased cellular responses could be explained by higher cell numbers, we analyzed complete blood counts (CBCs) and sought associations with cytokine responses. Total leukocytes-most markedly monocytes-were increased in the albendazole group compared with placebo at 9 mo posttreatment but not subsequently (Table S5 ). Leukocyte counts were positively associated with IL-2 to AscAg, however the rest were mainly negative associations, of which the one with TNF responses to PfRBC was significant. No association was found between monocyte numbers and cytokine responses to any of the stimuli (Table S6 ). This indicates that increased leukocyte numbers did not account for the general enhancement of cytokine responses. Moreover, when analysis of the treatment effect on cytokine responses was adjusted for leukocyte or monocyte counts, similar effect sizes were observed. No treatment effect was noted on other hematological parameters (Table S5) . 
Discussion
+ T cells in albendazole-treated children, indicating that immuno-inhibitory mechanisms could be affected by deworming.
The strongest effect of anthelmintic treatment was on antiplasmodial responses. These had not been specifically investigated in anthelmintic treatment RCTs. However, in cross-sectional studies examining the effect of helminths on malaria-specific cytokine responses, results are inconsistent (17) (18) (19) . The increase in response to malaria antigens could be due to a concurrent increase in malarial parasitemia in the albendazole-treated group 6 mo after initiation of treatment (20) , coincident with peak transmission season. By performing the analysis without malaria-positive subjects, we ruled out that this could explain the enhanced plasmodialspecific cytokine responses.
With regard to immune regulation, no treatment-related change in Treg frequencies was seen, consistent with the finding of similar Treg frequencies in STH-infected and -uninfected children reported from the same study area (12) . The proportion of PD-1-expressing CD4 + T cells was not significantly altered by albendazole treatment over 2 y, although in the first year posttreatment this was significantly lower. This is consistent with studies that show increased PD-1 expression is associated with helminth infections (13, 18) . The significant decrease in CTLA-4-expressing CD4 + T cells adds support to the important role of this molecule in suppression of immune responses in general and its suggested role in immune hyporesponsiveness induced by helminths (21) . When put in the context of the blockade of CTLA-4 (as well as PD-1) in treatment of melanoma and other cancers (22) , these findings lend further support to the suggested similarities between immunoregulation in chronic infectious diseases and cancers (23) . Three-monthly albendazole treatment over a 2-y period did not eliminate helminths. In earlier reports, the efficacy of one-time single or double doses of albendazole and/or mebendazole treatment has been low for Ascaris and Trichuris (24). Here we show that this is the case even after seven doses of albendazole at threemonthly intervals. By using a household-clustered randomization design, repeated treatments, and observed intake, we expected a more effective reduction in prevalence of STHs. For better deworming results, more intensive treatment or inclusion of environmental control would be needed. However, it is clear that even a 50% reduction in helminth infections in the community can start to reverse immune hyporesponsiveness and that more effective deworming might give even more pronounced immunological effects.
Subsequent to the increased proinflammatory responses after 9 mo, IL-5 and IL-10 responses increased 21 mo posttreatment. The analysis of the effect of anthelmintic treatment was stratified based on helminth infection status at baseline. By comparing the responses in the albendazole versus placebo group, the estimated outcome (beta) of the treatment effect after 9 and 21 mo of albendazole treatment was obtained. N, the number of the total population examined (N). An overall P value (P time ) is indicated for the effect of treatment over time. Statistically significant results (P < 0.05) are given in bold. *β (beta) and 95% CIs are based on linear mixed models. Estimates and β (beta) were obtained by linear mixed models; 95% CIs and overall P values over time (P time ) are indicated. As an indication of magnitude of change, the actual percentage of CTLA-4 + of CD4 + FOXP3 -cells in placebo and albendazole groups is shown at 9 mo (J).
Stratified analyses revealed that the increased mitogen-stimulated IL-5 and IL-10 was not specific to helminth-infected subjects, suggesting that factors other than the elimination of helminths may be responsible. This increased IL-10 response after 2 y of treatment might account for the fact that immune responses are not higher in the albendazole versus placebo at this time point. Enhanced cytokine responses could also be the result of a boosted immune response due to the release of antigens from dying or dead worms. However, the strongest increases in responses were not to worm antigen but to the unrelated malarial antigen. Moreover, using pretreatment worm burden as a proxy for antigen release, the modest increase seen to AscAg was not correlated with burden of Ascaris lumbricoides at pretreatment, nor were responses to nonrelated antigens correlated with baseline worm burden. These findings argue that observed boosted immune responses would not be due to release of antigens from dying worms, which has been shown to account for part of the increase in immune responses after treatment in schistosomiasis (25) , but rather be due to the decrease in immune regulation.
A number of factors other than reduction in helminths could contribute to the findings of this study, such as a direct effect of albendazole, alterations in immune cell counts, or changes in nutrients. Albendazole has been shown to affect cytokine responses in vitro (26) . The higher effect sizes in the stratified analysis of helminth-positives than those in the total group indicate that the enhancement of proinflammatory cytokine responses is unlikely to be due to albendazole directly affecting the immune system. Immune hyporesponsiveness could stem from alteration in cell counts and changes in nutrients essential to functioning of the immune system (27) . Although cell counts were affected by treatment, cell numbers did not account for cytokine responses. Because improved energy resources can enhance immune responses, we assessed body mass index (BMI) and fasting glucose level as proxies for nutritional status, but these parameters were not affected by deworming (20) .
Our study shows significant effects of deworming on the immune system. The effects could lead to enhanced immune responses to other pathogens and vaccines. With respect to vaccines, there is increasing concern regarding poor immunogenicity in rural areas of developing countries (28, 29) ; therefore, any measure to alleviate hyporesponsiveness would have a major public health impact. It is also important to consider the long-standing evolutionary coexistence between humans and helminths, the disturbance of which might lead to the emergence of pathological conditions (30) . However, for this outcome, long-rather than short-term treatment courses are expected to reveal any clinical impact (31) . Considering this, it will be important to include immunological measurements in future deworming programs and anthelmintic therapy trials to better understand and predict clinical outcomes.
Methods
Study Design. The study was nested within the ImmunoSPIN trial, a doubleblind placebo-controlled trial conducted in two villages on Flores island, Indonesia (20) . All households were randomized to receive either a single dose of 400 mg albendazole or placebo once every 3 mo for 2 y. Treatment was allocated to households to minimize the risk of reinfection and was provided to all household members older than 2 y, except for pregnant women, according to Indonesian guidelines. Intake was observed by field workers. Participants gave written informed or parental consent. The study was approved by the Ethics Committee of the Medical Faculty, University of Indonesia, Jakarta and was filed by the Ethics Committee of the Leiden University Medical Center, the Netherlands. The trial was registered as ISRCTN83830814.
Study Population. Randomization was based on 954 households in total, comprising 2,022 (481 houses) and 1,982 (473 houses) subjects in placebo and albendazole groups, respectively. For immunological studies, 250 households in the main village were randomly selected, and individuals older than 4 y of age were invited for venous blood sampling and assessment of anthropometric parameters. Thereby 882 individuals were included, of which 858 provided sufficient blood for whole-blood cultures. In the other village, 250 children were randomly selected from the total population, and children from the same households were also included, giving 295 children in total with whole-blood cultures. After cleaning the data (see Whole-Blood Culture and Cytokine Measurements), at baseline 839 and 220 subjects were included from the two areas, comprising 572 placebo-and 487 albendazole-treated individuals.
Because STH infection and associated immunological changes were anticipated to be most prevalent in school-age children, detailed analyses of regulatory components were only performed in this age group (4-12 y old). From a randomized selection separate from the previously mentioned subset, 145 children were included (71 randomized for placebo; 74 for albendazole), of which 121 (61 and 60, respectively) had sufficient numbers of cells. After 9 and 21 mo, 116 (56/60) and 107 (52/55) were followed up, respectively.
Whole-Blood Culture and Cytokine Measurements. Whole-blood was stimulated in vitro as described before (32) for 24 h (LPS stimulation) and 72 h [A. lumbricoides antigen (AscAg), PfRBCs, uRBCs, and PHA stimulations]. PfRBCs and uRBCs were prepared according to a standardized procedure (32) . AscAg was a homogenate of adult worm A. lumbricoides obtained from infected humans. Supernatants were stored at -20°C until quantification using Luminex kits (Biosource) on a Liquichip 200 Workstation (Qiagen). TNF and IL-10 were quantified in all supernatants, whereas IFN-γ, IL-2, and IL-5 were quantified only in 72-h supernatants. Samples with TNF levels ≥250 pg/mL in unstimulated blood were excluded from the analyses, as they were considered possibly contaminated. This cutoff value was derived from outliers in the data distribution. Cytokine concentrations below the assay's detectable range were replaced by half the detection limit provided by the manufacturer.
Stool Examination by Microscopy and PCR. Stool samples were collected annually. Trichuris trichiura was detected by microscopy after formolether concentration, whereas multiplex real-time PCR detected hookworm (Ancylostoma duodenale, Necator americanus), A. lumbricoides, and Strongyloides stercoralis DNA, as described previously (32) .
CBCs. CBCs before and 1 y posttreatment were determined using heparinized blood on a cell counter (Coulter Ac-T diff Analyzer, Beckman Coulter Inc.), whereas CBCs 2 y posttreatment were determined on a Sysmex KX-21N hematology analyzer (PT Sysmex Indonesia). Because both heparinized and EDTA blood samples were used at the last time point, 325 samples were tested in parallel analysis. All outcomes were highly comparable except for thrombocyte counts; thus, the data of all parameters but thrombocyte counts were pooled.
Flow Cytometry. Peripheral blood mononuclear cells (PBMCs) from 121 school children were isolated by Ficoll gradient centrifugation. PBMCs were fixed with FOXP3 Staining Buffer (eBioscience Inc.) and cryopreserved until further analysis. After thawing, cells were permeabilized and stained with anti-CD3, anti-CD4, anti-FOXP3, anti-CD25, anti-CTLA-4, anti-PD-1, and anti-Ki67 antibodies (Table S7 ). Data were acquired on a FACSCanto (BD Biosciences) and analyzed using FlowJo software (Treestar Inc.).
Statistical Analysis. Log transformation was used for cytokines [log10(concentration + 1)] and most flow cytometry [log10(value)] data to obtain normally distributed variables. For children's BMI, age-standardized z scores were calculated according to WHO references (33) . To assess treatment effects, linear mixed models were used; these are described in more detail in Statistical Analysis of Cytokine Responses. Parameter estimates and 95% CIs for treatment effects at 9 and 21 mo are reported. The analysis was intention-to-treat and involved all participants as assigned randomly at the start of the trial.
